Host STAT2/type i interferon axis controls tumor growth

International Journal of Cancer

Volumn 136, Issue 1, 2015, Pages 117-126

  Yue, Chanyu ^a   Xu, Jun ^a   Tan Estioko, Marc Daryl ^a   Kotredes, Kevin P ^a   Lopez Otalora, Yolanda ^a   Hilliard, Brendan A ^a   Baker, Darren P ^b   Gallucci, Stefania ^a   Gamero, Ana M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BIOGEN   (United States)

Author keywords

antitumor; cross presentation; dendritic cell; interferon; melanoma; STAT1; STAT2

Indexed keywords

BETA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; INTERFERON; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; TUMOR ANTIGEN; ANTINEOPLASTIC AGENT; CULTURE MEDIUM; STAT1 PROTEIN, MOUSE; STAT2 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; CULTURE MEDIUM; DENDRITIC CELL; DOWN REGULATION; GENE EXPRESSION; IMMUNOMODULATION; LUNG METASTASIS; MELANOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR REGRESSION; WILD TYPE; 129 MOUSE; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY; PHYSIOLOGY; SECONDARY; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR VOLUME;

ADOPTIVE TRANSFER; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DENDRITIC CELLS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERFERON-BETA; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 84925283155     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29004     Document Type: Article

References (42)

1. Fu XY, Schindler C, Improta T, et al., The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci USA 1992; 89: 7840-3.
2. Schindler C, Shuai K, Prezioso VR, et al., Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 1992; 257: 809-13.
3. Darnell JE, Jr,., Kerr IM, Stark GR., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-21.
4. Stark GR, Kerr IM, Williams BR, et al., How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-64.
5. Levy DE, Darnell JE, Jr,. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-62.
6. Clifford JL, Yang X, Walch E, et al., Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon alpha action in skin squamous cell carcinoma cells. Mol Cancer Ther 2003; 2: 453-9.
7. Du Z, Fan M, Kim JG, et al., Interferon-resistant Daudi cell line with a Stat2 defect is resistant to apoptosis induced by chemotherapeutic agents. J Biol Chem 2009; 284: 27808-15.
8. Gamero AM, Larner AC,. Vanadate facilitates interferon alpha-mediated apoptosis that is dependent on the Jak/Stat pathway. J Biol Chem 2001; 276: 13547-53.
9. Romero-Weaver AL, Wang HW, Steen HC, et al., Resistance to IFN-alpha-induced apoptosis is linked to a loss of STAT2. Mol Cancer Res 2010; 8: 80-92.
10. Park C, Li S, Cha E, et al., Immune response in Stat2 knockout mice. Immunity 2000; 13: 795-804.
11. Gimeno R, Lee CK, Schindler C, et al., Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes. Mol Cell Biol 2005; 25: 5456-65.
12. Plumlee CR, Lee C, Beg AA, et al., Interferons direct an effective innate response to Legionella pneumophila infection. J Biol Chem 2009; 284: 30058-66.
13. Gamero AM, Young MR, Mentor-Marcel R, et al., STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev Res (Phila) 2010; 3: 495-504.
14. Wang J, Pham-Mitchell N, Schindler C, et al., Dysregulated Sonic hedgehog signaling and medulloblastoma consequent to IFN-alpha-stimulated STAT2-independent production of IFN-gamma in the brain. J Clin Invest 2003; 112: 535-43.
15. Picaud S, Bardot B, De Maeyer E, et al., Enhanced tumor development in mice lacking a functional type I interferon receptor. J Interferon Cytokine Res 2002; 22: 457-62.
16. Takemoto Y, Yano H, Momosaki S, et al., Antiproliferative effects of interferon-alphaCon1 on ovarian clear cell adenocarcinoma in vitro and in vivo. Clin Cancer Res 2004; 10: 7418-26.
17. Hisaka T, Yano H, Ogasawara S, et al., Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo. J Hepatol 2004; 41: 782-9.
18. Dunn GP, Bruce AT, Sheehan KC, et al., A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6: 722-9.
19. Swann JB, Hayakawa Y, Zerafa N, et al., Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007; 178: 7540-9.
20. Diamond MS, Kinder M, Matsushita H, et al., Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208: 1989-2003.
21. Fuertes MB, Kacha AK, Kline J, Woo, et al., Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011; 208: 2005-16.
22. Chen LS, Wei PC, Liu T, et al., STAT2 hypomorphic mutant mice display impaired dendritic cell development and antiviral response. J Biomed Sci 2009; 16: 22.
23. Sriram U, Biswas C, Behrens EM, et al., IL-4 suppresses dendritic cell response to type I interferons. J Immunol 2007; 179: 6446-55.
24. Yue C, Soboloff J, Gamero AM,. Control of type I interferon-induced cell death by Orai1-mediated calcium entry in T cells. J Biol Chem 2012; 287: 3207-16.
25. Simon R, Lam A, Li MC, et al., Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007; 3: 11-7.
26. Lesinski GB, Anghelina M, Zimmerer J, et al., The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 2003; 112: 170-80.
27. Dauffy J, Mouchiroud G, Bourette RP,. The interferon-inducible gene, Ifi204, is transcriptionally activated in response to M-CSF, and its expression favors macrophage differentiation in myeloid progenitor cells. J Leukoc Biol 2006; 79: 173-83.
28. Petro M, Kish D, Guryanova OA, et al., Cutaneous tumors cease CXCL9/Mig production as a result of IFN-gamma-mediated immunoediting. J Immunol 2013; 190: 832-41.
29. Overwijk WW, Theoret MR, Finkelstein SE, et al., Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003; 198: 569-80.
30. Klebanoff CA, Gattinoni L, Palmer DC, et al., Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res 2011; 17: 5343-52.
31. Roychowdhury S, May KF, Jr,., Tzou KS, et al., Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res 2004; 64: 8062-7.
32. Sikora AG, Jaffarzad N, Hailemichael Y, et al., IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol 2009; 182: 7398-407.
33. Burnette BC, Liang H, Lee Y, et al., The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 2011; 71: 2488-96.
34. Wang S, Zhang X, Ju Y, et al., MicroRNA-146a feedback suppresses T cell immune function by targeting Stat1 in patients with chronic hepatitis B. J Immunol 2013; 191: 293-301.
35. Clifford JL, Walch E, Yang X, et al., Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res 2002; 8: 2067-72.
36. Obrador E, Benlloch M, Pellicer JA, et al., Intertissue flow of glutathione (GSH) as a tumor growth-promoting mechanism: interleukin 6 induces GSH release from hepatocytes in metastatic B16 melanoma-bearing mice. J Biol Chem 2011; 286: 15716-27.
37. Lembo M, Sacchi C, Zappador C, et al., Inhibition of cell proliferation by the interferon-inducible 204 gene, a member of the Ifi 200 cluster. Oncogene 1998; 16: 1543-51.
38. Guirnalda P, Wood L, Goenka R, et al., Interferon gamma-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with. Oncoimmunology 2013; 2: e25752.
39. Padovan E, Spagnoli GC, Ferrantini M, et al., IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol 2002; 71: 669-76.
40. Montoya M, Schiavoni G, Mattei F, et al., Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002; 99: 3263-71.
41. Asselin-Paturel C, Brizard G, Chemin K, et al., Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med 2005; 201: 1157-67.
42. Swiecki M, Wang Y, Vermi W, et al., Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med 2011; 208: 2367-74.